Pharawee Wandee

Pharawee Wandee

Auto-generated profile, based on publicly available information

Pharawee Wandee

Center of Excellence in Arrhythmia Research Chulalongkorn University, Department of Medicine, Faculty of Medicine, Chulalongkorn University , 1873 Rama IV Rd., Pathum Wan, Bangkok 10330

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2022 in Genomics & Informatics
Verified
Journal Article
Open access
PDF file
SCSuwalak Chitcharoen
Suwalak Chitcharoen
CPChureerat Phokaew
Chureerat Phokaew
JMJohn Mauleekoonphairoj
John Mauleekoonphairoj
AKApichai Khongphatthanayothin
Apichai Khongphatthanayothin
BSBoosamas Sutjaporn
Boosamas Sutjaporn
SPSunchai Payungporn
Sunchai Payungporn
Brugada syndrome (BS) is an autosomal dominant inheritance cardiac arrhythmia disorder associated with sudden death in young adults. Thailand has the highest prevalence of BS worldwide, and over 60% of patients with BS still have unclear disease etiology. Here, we performed a new viral metagenome analysis pipeline called VIRIN and validated it with whole genome sequencing (WGS) data of HeLa cell lines and hepatocellular carcinoma. Then the VIRIN pipeline was applied to identify viral integration positions from unmapped WGS data of Thai males, including 100 BS patients (case) and 100 controls. Even though the sample preparation had no viral enrichment step, we can identify several virus genes from our analysis pipeline. The predominance of human endogenous retrovirus K (HERV-K) viruses was found in both cases and controls by blastn and blastx analysis. This study is the first report on the full-length HERV-K assembled genomes in the Thai population. Furthermore, the HERV-K integration breakpoint positions were validated and compared between the case and control datasets. Interestingly, Brugada cases contained HERV-K integration breakpoints at promoters five times more often than controls. Overall, the highlight of this study is the BS-specific HERV-K breakpoint positions that were found at the gene coding region "NBPF11" (n = 9), "NBPF12" (n = 8) and long non-coding RNA (lncRNA) "PCAT14" (n = 4) region. The genes and the lncRNA have been reported to be associated with congenital heart and arterial diseases. These findings provide another aspect of the BS etiology associated with viral genome integrations within the human genome.

1 December 2025 in PNAS Nexus
Verified
Journal Article
Open access
VAVichaya Auvichayapat
Vichaya Auvichayapat
SLSarin Lekchuensakul
Sarin Lekchuensakul
PWPharawee Wandee
Pharawee Wandee
JMJohn Mauleekoonphairoj
John Mauleekoonphairoj
SVSirikorn Vongseenin
Sirikorn Vongseenin
SBSaknan Bongsebandhu-Phubhakdi
Saknan Bongsebandhu-Phubhakdi
Long QT syndrome type 3 (LQTS3), caused by gain-of-function mutations in the SCN5A gene, encompasses a spectrum of clinical presentations, ranging from asymptomatic carriers to severe arrhythmic phenotypes, representing the “silent killer” and “brutal killer” dichotomy. The p.I239V mutation is associated with mild symptoms and minimal arrhythmic events, whereas the newly identified p.M1487K mutation is linked to life-threatening arrhythmic storms. This study aimed to explore the electrophysiological properties of these mutations and their responses to sodium channel blockers to advance precision medicine in LQTS3 management. Genetic analysis identified rare SCN5A mutations in two LQTS3 patients. Site-directed mutagenesis was used to construct mutant SCN5A plasmids, which were expressed in HEK293 cells. Electrophysiological properties were analyzed using patch-clamp techniques, and pharmacological responses to flecainide, mexiletine, and ranolazine were evaluated. Electrophysiological recordings correlated with clinical presentations. Both mutations showed increased window INa and faster recovery from inactivation. The p.I239V mutation lacked sustained INa, while p.M1487K exhibited significantly increased sustained INa (2.3 ± 2.15%, P < 0.0001). Mexiletine and ranolazine effectively reduced sustained INa by 76.15 ± 5.83, and 77.63 ± 9.41%, respectively, outperforming flecainide, aligning with clinical responses. This study highlights the role of sustained INa in LQTS3 severity and underscores the importance of mutation-specific treatments. By tailoring treatments to the electrophysiological characteristics of each mutation, precision medicine offers a promising approach to improving patient outcomes in LQTS3.